Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

* Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy
Positive high-level results from the FLAURA2 Phase III trial... | May 17, 2023

Related Keywords

United States ,United Kingdom ,Poland ,China ,Japan ,Cambridge ,Cambridgeshire ,Polish ,American ,America ,Daiichi Sankyo ,Astrazeneca Tagrisso ,Adrian Kemp ,Susan Galbraith ,Company On Twitter Astrazeneca ,Lung Ambition Alliance ,Archives Pathology Lab ,World Health Organisation ,Nasdaq ,Lungevity Foundation ,Astrazeneca ,Dana Farber Cancer Institute ,Single Institution Study ,International Agency For Research On Cancer ,Investor Relations Team ,Farber Cancer Institute ,Executive Vice President ,Ambition Alliance ,Rare Diseases ,Lung Fact ,Histological Samples ,Non Small Cell ,Systematic Review ,Intj Clin Exp ,Clinical Oncology Provisional Opinion ,Epidermal Growth Factor Receptor ,Mutation Testing ,Kinase Inhibitor ,Available Methods ,Their Use ,Tumour Tissue ,Cancer Biomarkers ,Present Status ,Mediated Resistance ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,Results ,Support ,Potential ,Or ,Few ,Treatment ,Option ,Hat ,Builds ,N ,The ,Benefit ,F ,Standard ,Mare ,Tagrisso ,Rom ,Flaura2 ,Hase ,Ii Azn Gb0009895292 ,